PUBLIC COMPANY
save$AMLXAmylyx Pharmaceuticals, Inc.
Cambridge, MA, USupdated 1mo ago
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.
community read0 votes
pipeline
3
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 11Phase 21Phase 3
comments(0)
5-min edit window · permanent after that